Embecta Corp. 8K

Embecta Corp. reported weaker year-over-year but stronger sequential Q3 2026 results, completed the Owen Mumford acquisition, repaid debt and repurchased shares, reaffirmed revenue guidance, and raised full-year adjusted margin and EPS guidance while declaring a $0.01 dividend.

On August 7, 2026, Embecta Corp. reported its fiscal third quarter 2026 results and updated full-year guidance, highlighting a sequential improvement in revenue and profitability driven partly by the mid-quarter completion of its acquisition of Owen Mumford Holdings Limited, despite year-over-year declines in revenues, gross margin, operating income, and earnings. The company detailed third-quarter revenue of $271.7 million (down 8.1% year-over-year), significant declines in U.S. sales offset by double-digit international growth, and adjusted EBITDA margin compression versus the prior year, while noting repayment of approximately $53 million of debt, share repurchases of about $9 million under its three-year $100 million buyback program, and the declaration of a $0.01 per-share quarterly dividend. Embecta reaffirmed its fiscal 2026 revenue outlook of $1,015–$1,035 million but raised guidance for adjusted operating margin (to 23.5%–24.0%) and adjusted EPS (to $1.80–$1.90), incorporating roughly four and a half months of contribution from Owen Mumford and ongoing brand transition and product initiatives, including regulatory progress on pen needles, launches of syringes in selected markets, expansion of GLP-1-related co-packaging in multiple countries, and planned U.S. launch of a GLP-1 small pack format in the fourth quarter.

Filing Facts

CIK

1872789

Ticker

-

Form

8K

Source Type

sec

Accession

0001872789-26-000029

Alert Tier

7